Get the Stockscreener App
0.1798
0.28%
0.0005
After Hours:
.18
0.0002
+0.11%
Aptevo Therapeutics Inc stock is traded at $0.1798, with a volume of 339.71K.
It is up +0.28% in the last 24 hours and down -50.06% over the past month.
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
See More
Previous Close:
$0.1793
Open:
$0.1793
24h Volume:
339.71K
Relative Volume:
0.05
Market Cap:
$1.70M
Revenue:
$12.99M
Net Income/Loss:
$-17.41M
P/E Ratio:
-0.0547
EPS:
-3.29
Net Cash Flow:
$-11.73M
1W Performance:
+2.33%
1M Performance:
-50.06%
6M Performance:
-96.17%
1Y Performance:
-98.76%
1-Day Range:
$0.1751
$0.184
1-Week Range:
$0.165
$0.19
52-Week Range:
$0.141
$21.56
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Name
Aptevo Therapeutics Inc
Sector
Industry
Phone
206-838-0500
Address
2401 4TH AVE., SEATTLE, WA
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-18 | Initiated | Ladenburg Thalmann | Buy |
| Oct-05-17 | Resumed | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Stock (APVO) Latest News
Certain Common Warrants of Aptevo Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-SEP-2024. - Marketscreener.com
Aptevo Therapeutics (NASDAQ:APVO) Stock Quotes, Forecast and News Summary - Benzinga
Aptevo Therapeutics (NASDAQ:APVO) Now Covered by StockNews.com - Defense World
Aptevo Therapeutics Inc Inc. (APVO) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Down 78.8% in September - Defense World
Short Interest in Advantest Co. (OTCMKTS:ATEYY) Declines By 85.7% - MarketBeat
Applied Therapeutics (NASDAQ:APLT) Stock Price Up 5.2% - Defense World
Astria Therapeutics (NASDAQ:ATXS) Shares Gap Down to $12.50 - MarketBeat
DRW Securities LLC Invests $117,000 in Patterson-UTI Energy, Inc. (NASDAQ:PTEN) - Defense World
There is no doubt that Aptevo Therapeutics Inc (APVO) ticks all the boxes. - SETE News
Gabelli Funds LLC Raises Stake in Aptiv PLC (NYSE:APTV) - Defense World
Aptevo Therapeutics Inc. (NASDAQ:APVO) to Post Q3 2024 Earnings of ($0.57) Per Share, Roth Capital Forecasts - Defense World
Aptiv PLC stock rises Tuesday, outperforms market - MarketWatch
Logos Global Management LP Sells 750,000 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Patterson-UTI Energy (NASDAQ:PTEN) Shares Down 3.5% - Defense World
PTEN’s Q2 earnings estimates: What investors need to know - US Post News
PTEN’s Market Whiplash: -22.96% YTD Decline, -10.63% Plunge in 30 Days - The InvestChronicle
Aptar's N-Sorb accepted into FDA Emerging Technology Program - Investing.com India
Did Aptevo Therapeutics Inc (APVO) perform well in the last session? - US Post News
Aptiv PLC (NYSE:APTV) Shares Sold by Summit Trail Advisors LLC - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Sold by Logos Global Management LP - MarketBeat
Benjamin F. Edwards & Company Inc. Grows Position in Aptiv PLC (NYSE:APTV) - Defense World
New RNA specialist launches in Milan with $1.6 million - The Pharma Letter
Launch of Aptadir Therapeutics With a Novel Class of RNA Inhibitors - Business Wire
Roth/MKM cuts Aptevo Therapeutics stock target, keeps Buy on clinical trial - Investing.com Canada
Recent Insider Activity Suggests Potential Gains for Aptiv PLC (APTV) - Knox Daily
Patterson-UTI Energy Inc [PTEN] is -22.50% lower this YTD. Is it still time to buy? - The DBT News
Research Analysts’ Price Target Changes for September 23rd (ADUS, AIT, AIZ, ALLY, AMRC, AMT, APLS, APVO, ASND, BA) - Defense World
Aptevo Therapeutics (NASDAQ:APVO) Price Target Cut to $8.00 - Defense World
Davidson Kempner Capital Management LP Invests $6.69 Million in Aptiv PLC (NYSE:APTV) - Defense World
Aptevo Therapeutics price target lowered to $8 from $15 at Roth MKM - TipRanks
Quarterly Snapshot: Quick and Current Ratios for Aptevo Therapeutics Inc (APVO) - The Dwinnex
Prospector Partners LLC Boosts Stock Position in Aptiv PLC (NYSE:APTV) - MarketBeat
Sompo Asset Management Co. Ltd. Reduces Holdings in Aptiv PLC (NYSE:APTV) - Defense World
Aptiv PLC (NYSE:APTV) Shares Sold by Bradley Foster & Sargent Inc. CT - Defense World
Aptiv PLC (NYSE:APTV) Stake Lessened by Dimensional Fund Advisors LP - Defense World
Tredje AP fonden Lowers Stock Position in Aptiv PLC (NYSE:APTV) - Defense World
Aptiv (APTV) Navigates EV Market Hurdles with 28% Earnings Growth - Insider Monkey
Applied Therapeutics (NASDAQ:APLT) Sees Large Volume Increase Following Analyst Upgrade - Defense World
Leerink Partners Raises Applied Therapeutics (NASDAQ:APLT) Price Target to $14.00 - MarketBeat
Baird highlights PDUFA progress driving optimism for Applied Therapeutics stock - Investing.com Australia
Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha
Applied Therapeutics stock surges after FDA update - The Pharma Letter
Applied Therapeutics, Inc. (NASDAQ:APLT) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
StockNews.com Begins Coverage on Aptevo Therapeutics (NASDAQ:APVO) - Defense World
Applied Therapeutics (NASDAQ:APLT) Trading Down 4.1% - Defense World
Aptevo Therapeutics stock plunges to 52-week low of $0.18 - Investing.com
Applied Therapeutics Surges on Positive FDA Update for Govorestat - BP Journal
Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules - AccessWire
Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules - StockTitan
Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review (APLT) - Seeking Alpha
Aptevo Therapeutics Inc Stock (APVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):